CytoSorbents Q3 2023 EPS $(0.21) Misses $(0.12) Estimate, Sales $8.81M Miss $9.49M Estimate
Portfolio Pulse from totan@benzinga.com
CytoSorbents (NASDAQ:CTSO) reported Q3 2023 earnings per share (EPS) of $(0.21), missing the analyst consensus estimate of $(0.12) by 75%. The company also reported quarterly sales of $8.81 million, missing the estimate of $9.49 million by 7.15%. However, both EPS and sales showed an increase compared to the same period last year.
November 09, 2023 | 9:48 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CytoSorbents reported a larger than expected loss and lower than expected sales for Q3 2023. Despite year-over-year improvements, the miss may negatively impact the stock in the short term.
CytoSorbents reported a larger loss per share and lower sales than analysts had estimated for Q3 2023. While the company did show improvements compared to the same period last year, the miss on both fronts is likely to put downward pressure on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100